Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

J. Nemunaitis · SciRah

Researcher profile · Semantic Scholar

J. Nemunaitis

Share profile

J. Nemunaitis — researcher profile on SciRah

h-index: 88
Works: 592
Citations: 31K

Most-cited papers

Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
David H. Johnson, L. Fehrenbacher, W. Novotny, R. Herbst +8 more
2023Journal of Clinical Oncology655 citations
Semantic Scholar
Ovarian Cancer Immunotherapy and Personalized Medicine
Susan Morand, Monika Devanaboyina, H. Staats, L. Stanbery +1 more
2021International Journal of Molecular Sciences328 citations Open access
Semantic Scholar
STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial.
M. Reilley, P. McCoon, C. Cook, P. Lyne +23 more
2018Journal of Immunotherapy for Cancer226 citations Open access
Semantic Scholar
Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy
Ali J Alqahtani, Khalil Choucair, M. Ashraf, Danae M. Hammouda +4 more
2019Future Science OA225 citations Open access
Semantic Scholar
Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial
R. Hassan, Anish Thomas, J. Nemunaitis, M. Patel +13 more
2019JAMA Oncology160 citations Open access
Semantic Scholar
TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials
Khalil Choucair, Susan Morand, L. Stanbery, G. Edelman +2 more
2020Cancer Gene Therapy154 citations
Semantic Scholar
First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody–Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors
R. Hassan, G. Blumenschein, K. Moore, A. Santin +12 more
2020Journal of Clinical Oncology136 citations Open access
Semantic Scholar
The abscopal effect of radiation therapy.
D. J. Craig, Nisha S Nanavaty, Monika Devanaboyina, L. Stanbery +4 more
2021Future Oncology114 citations Open access
Semantic Scholar
First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.
J. Strickler, C. Weekes, J. Nemunaitis, R. Ramanathan +11 more
2018Journal of Clinical Oncology113 citations Open access
Semantic Scholar
Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial.
R. Rocconi, E. Grosen, S. Ghamande, J. Chan +19 more
2020The Lancet Oncology103 citations
Semantic Scholar
Clinical Activity, Tolerability, and Long-term Follow-up of Durvalumab in Patients With Advanced NSCLC.
S. Antonia, A. Balmanoukian, J. Brahmer, S. Ou +27 more
2019Journal of Thoracic Oncology90 citations Open access
Semantic Scholar
Folate Receptor as a Biomarker and Therapeutic Target in Solid Tumors.
Olivia Young, N. Ngo, Le Lin, L. Stanbery +3 more
2022Current Problems in Cancer86 citations Open access
Semantic Scholar
Homologous recombination proficiency in ovarian and breast cancer patients
J. Creeden, Nisha S Nanavaty, Katelyn R. Einloth, C. Gillman +4 more
2021BMC Cancer83 citations Open access
Semantic Scholar
First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy
P. Munster, M. Mita, A. Mahipal, J. Nemunaitis +16 more
2019Cancer Management and Research79 citations Open access
Semantic Scholar
NF-κB Signaling in Tumor Pathways Focusing on Breast and Ovarian Cancer
Monika Devanaboyina, J. Kaur, Emma S. Whiteley, Le Lin +5 more
2022Oncology Reviews68 citations Open access
Semantic Scholar
Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma
R. Andtbacka, T. Amatruda, J. Nemunaitis, J. Zager +6 more
2019EBioMedicine67 citations Open access
Semantic Scholar
Current Ovarian Cancer Maintenance Strategies and Promising New Developments
Vinaya Gogineni, Susan Morand, H. Staats, Rachel Royfman +10 more
2021Journal of Cancer64 citations Open access
Semantic Scholar
A randomized phase 2 trial of epigenetic priming with guadecitabine and carboplatin in platinum-resistant, recurrent ovarian cancer
A. Oza, U. Matulonis, Angeles Alvarez Secord, J. Nemunaitis +24 more
2019Clinical Cancer Research61 citations Open access
Semantic Scholar
Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies.
S. Ansell, I. Flinn, M. Taylor, B. Sikic +7 more
2020Blood Advances60 citations Open access
Semantic Scholar
Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib.
J. Nemunaitis, S. Bauer, J. Blay, Khalil Choucair +8 more
2019Future Oncology49 citations Open access
Semantic Scholar
Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor Activity
D. Mahalingam, Judy S. Wang, E. Hamilton, J. Sarantopoulos +6 more
2019Clinical Cancer Research49 citations Open access
Semantic Scholar
Brief Report: Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination with Pegilodecakin in Patients with Metastatic Non-Small-Cell Lung Cancer (CYPRESS-1 and CYPRESS-2).
D. Spigel, R. Jotte, J. Nemunaitis, M. Shum +16 more
2020Journal of Thoracic Oncology45 citations Open access
Semantic Scholar
Randomized, double‐blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer
D. Fogelman, A. Cubillo, P. García-Alfonso, M. L. Mirón +11 more
2018Cancer Medicine41 citations Open access
Semantic Scholar
Adenomatous polyposis coli in cancer and therapeutic implications
Olivia Noe, L. Filipiak, Rachel Royfman, A. Campbell +4 more
2021Oncology Reviews38 citations Open access
Semantic Scholar
Natural killer cells: a Review of biology, therapeutic potential and challenges in treatment of solid tumors.
Khalil Choucair, Joseph R. Duff, C. Cassidy, Mary Albrethsen +7 more
2019Future Oncology37 citations
Semantic Scholar
Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer.
R. Rocconi, B. Monk, Adam Walter, T. Herzog +9 more
2021Gynecologic Oncology33 citations
Semantic Scholar
Molecular mechanisms underlying rheumatoid arthritis and cancer development and treatment.
Susan Morand, H. Staats, J. Creeden, Azwar K. Iqbal +4 more
2020Future Oncology30 citations
Semantic Scholar
A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms
E. Wolin, A. Mita, A. Mahipal, T. Meyer +9 more
2019PLoS ONE29 citations Open access
Semantic Scholar
Safety and clinical activity of durvalumab monotherapy in patients with microsatellite instability–high (MSI-H) tumors.
N. Segal, Z. Wainberg, M. Overman, P. Ascierto +15 more
2019Journal of Clinical Oncology28 citations
Semantic Scholar
Resident Memory T Cells and Their Effect on Cancer
D. J. Craig, J. Creeden, Katelyn R. Einloth, C. Gillman +5 more
2020Vaccines27 citations Open access
Semantic Scholar
Analysis of Adenoviral p53 Gene Therapy Clinical Trials in Recurrent Head and Neck Squamous Cell Carcinoma
R. E. Sobol, K. Menander, S. Chada, D. Wiederhold +3 more
2021Frontiers in Oncology25 citations Open access
Semantic Scholar
Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study
M. Taylor, Courtney B. Betts, Lauren Maloney, E. Nadler +11 more
2021Clinical Cancer Research24 citations Open access
Semantic Scholar
Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance
Johnathan Oh, M. Barve, N. Senzer, P. Aaron +9 more
2020Gynecologic Oncology Reports24 citations Open access
Semantic Scholar
Tumor suppressor immune gene therapy to reverse immunotherapy resistance
S. Chada, D. Wiederhold, K. Menander, Beatha Sellman +6 more
2021medRxiv23 citations Open access
Semantic Scholar
Bifidobacterium spp: the promising Trojan Horse in the era of precision oncology.
N. Ngo, Khalil Choucair, J. Creeden, Hanan Qaqish +9 more
2019Future Oncology23 citations
Semantic Scholar
Pilot Study of Recurrent Ewing's Sarcoma Management with Vigil/Temozolomide/Irinotecan and Assessment of Circulating Tumor (ct) DNA
P. Anderson, Maurizio Ghisoli, Brian D. Crompton, Kelly S. Klega +9 more
2023Clinical Cancer Research22 citations Open access
Semantic Scholar
Repurposing Metformin, Simvastatin and Digoxin as a combination for Targeted therapy of Pancreatic Ductal Adenocarcinoma
Shi-he Liu, Jue-Hua Yu, J. Creeden, Jeffrey M. Sutton +8 more
2020Cancer Letters22 citations Open access
Semantic Scholar
BIRC5 is a target for molecular imaging and detection of human pancreatic cancer.
Shi-he Liu, Yeahwa Hong, S. Markowiak, R. Sanchez +8 more
2019Cancer Letters22 citations
Semantic Scholar
Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer
R. Rocconi, E. E. Stevens, J. Bottsford-Miller, S. Ghamande +16 more
2021Cancer Gene Therapy21 citations
Semantic Scholar
Chimeric Antigen Receptor T-Cell Therapy: Reach to Solid Tumor Experience
Matthew N. Metzinger, C. Verghese, D. Hamouda, A. Lenhard +5 more
2019Oncology21 citations
Semantic Scholar
Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer
M. Barve, P. Aaron, L. Manning, E. Bognar +4 more
2022Clinical Medicine Insights: Oncology20 citations Open access
Semantic Scholar
Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer
A. Tsimberidou, J. Shaw, D. Juric, C. Verschraegen +11 more
2021Journal of Hematology & Oncology20 citations Open access
Semantic Scholar
Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer.
Adam Walter, R. Rocconi, B. Monk, T. Herzog +9 more
2021Gynecologic Oncology19 citations Open access
Semantic Scholar
BRCA1/2 Mutation Status Impact on Autophagy and Immune Response: Unheralded Target
Susan Morand, L. Stanbery, Adam Walter, R. Rocconi +1 more
2020JNCI Cancer Spectrum19 citations Open access
Semantic Scholar
Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study
A. Naing, J. Powderly, J. Nemunaitis, J. Luke +10 more
2022Journal for ImmunoTherapy of Cancer17 citations Open access
Semantic Scholar
Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors
J. Nemunaitis, Annie M. Young, S. Ejadi, W. Miller +6 more
2018Cancer Chemotherapy and Pharmacology17 citations
Semantic Scholar
Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer
R. Rocconi, L. Stanbery, L. Madeira da Silva, R. Barrington +7 more
2021Vaccines16 citations Open access
Semantic Scholar
BRCA1/2 signaling and homologous recombination deficiency in breast and ovarian cancer.
Rachel Royfman, Emma S. Whiteley, Olivia Noe, Susan Morand +4 more
2021Future Oncology16 citations
Semantic Scholar
Subclonal landscape of cancer drives resistance to immune therapy.
D. J. Craig, Morgan Bailey, Olivia Noe, Kada K Williams +3 more
2022Cancer Treatment and Research Communications15 citations Open access
Semantic Scholar
Vigil: Personalized Immunotherapy Generating Systemic Cytotoxic T Cell Response
J. Herron, N. Smith, L. Stanbery, P. Aaron +5 more
2020Cancer Science & Research15 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

L. Stanbery×23
Invite
L. Stanbery — researcher profile on SciRah
L. Manning×10
Invite
L. Manning — researcher profile on SciRah
L. Dworkin×9
Invite
L. Dworkin — researcher profile on SciRah
D. Hamouda×9
Invite
D. Hamouda — researcher profile on SciRah

×9

Invite

P. Aaron — researcher profile on SciRah

G. Wallraven×9

Invite

G. Wallraven — researcher profile on SciRah

Invite

E. Bognar — researcher profile on SciRah

Staci Horvath×8

Invite

Staci Horvath — researcher profile on SciRah

Invite

J. Creeden — researcher profile on SciRah

Susan Morand×7

Invite

Susan Morand — researcher profile on SciRah

Invite

R. Rocconi — researcher profile on SciRah

Invite

Adam Walter — researcher profile on SciRah